Valion Bio, Inc.
Key Metrics
Market Snapshot
About
Valion Bio, Inc. (VBIO) is a late-stage biopharmaceutical company based in San Antonio, Texas. The company was incorporated in 2016 and previously operated as Tivic Health Systems, Inc. before changing its name to Valion Bio, Inc. in April 2026. It is known for developing drug candidates centered on a compound called Entolimod, with a focus on conditions related to the immune system and radiation exposure.
The company's lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development as a treatment for acute radiation syndrome. Beyond this lead program, Valion Bio is also studying Entolimod for the treatment of neutropenia and lymphocyte exhaustion, broadening the range of conditions the compound may address. Its pipeline further includes Entolasta, described as an immunologically optimized variant of Entolimod intended for chronic applications such as immunosenescence, which relates to the decline of immune function over time.
In addition to advancing its own pipeline, the company offers contract development and manufacturing organization, or CDMO, services. This means it can provide development and manufacturing support to other parties alongside pursuing its internal programs, giving it a service line in addition to its drug candidates. As a late-stage biopharmaceutical company, Valion Bio is centered on moving its Entolimod-based candidates through development toward potential approval and use. Its prospects rest on the progress of these programs across acute radiation syndrome and immune-related conditions, together with the contribution from its CDMO activities. The recent name change from Tivic Health Systems marks the company's identity as a biopharmaceutical developer built around its immunology-focused pipeline.